Correct performance of subcutaneous injections in plaque psoriasis: comparison of trained and untrained patients with different application systems in routine clinical care

References

• Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136–139.
   PubMed Web of Science ®Google Scholar
• Augustin M, Krüger K, Radtke MA, et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology. 2008;216(4):366–372.
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3):401–407.
   PubMed Web of Science ®Google Scholar
• Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis. Expert Rev Dermatol. 2006;1(1):63–75.
   Google Scholar
• Schäfer I, Rustenbach SJ, Radtke M, et al. Epidemiologie der Psoriasis in Deutschland - Auswertung von Sekundärdaten einer gesetzlichen Krankenversicherung. Gesundheitswesen. 2011;73(05):308–313.
   PubMedGoogle Scholar
• Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25:9–14.
   PubMed Web of Science ®Google Scholar
• Ali SM, Brodell RT, Balkrishnan R, et al. Poor adherence to treatments: a fundamental principle of dermatology. Arch Dermatol. 2007;143(7):846–850.
   PubMedGoogle Scholar
• Augustin M, Holland B, Dartsch D, et al. Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011;222(4):363–374.
   PubMed Web of Science ®Google Scholar
• Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55(4):607–613.
   PubMed Web of Science ®Google Scholar
• Enk AM, Kiedrowski V, Körber R, et al. Einsatz von Systemtherapeutika und Biologika in der leitliniengerechten Therapie der mittelschweren bis schweren Psoriasis vulgaris. PsoNet Magazin. 2017;4(Suppl 1):1–28.
   Google Scholar
• Nast A, Kopp IB, Augustin M, et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. J Dtsch Dermatol Ges. 2006;4:1–126.
   Google Scholar
• Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277–2294.
   PubMed Web of Science ®Google Scholar
• Nast A, Spuls PI, Van Der Kraaij G, et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC Funding sources. J Eur Acad Dermatol Venereol. 2017;31(12):1951–1963.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Del Giglio M, Girolomoni G. Treatment approaches to moderate to severe psoriasis. Int J Mol Sci. 2017;18(11):2427.
   PubMed Web of Science ®Google Scholar
• Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177(3):628–636.
   PubMed Web of Science ®Google Scholar
• Ramaekers BLT, Wolff RF, Pouwels X, et al. Ixekizumab for treating moderate-to-severe plaque psoriasis: an evidence review group perspective of a nice single technology appraisal. Pharmacoeconomics. 2018;36:917–927.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76 (3):418–431.
   PubMed Web of Science ®Google Scholar
• Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–123.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598–606.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139(12):1627–1632.
   PubMed Web of Science ®Google Scholar
• Dooren-Greebe RJ, Kuijpers ALA, Mulder J, et al. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol. 1994;130(2):204–210.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, the FEATURE Study Group, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484–493.
   PubMed Web of Science ®Google Scholar
• Paul C, the JUNCTURE study group, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082–1090.
   PubMed Web of Science ®Google Scholar
• Paul C, Stalder JF, Thaçi D, et al. Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2012;26(4):448–455.
   PubMed Web of Science ®Google Scholar
• Kivitz A, Cohen S, Dowd JE, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther. 2006;28(10):1619–1629.
   PubMed Web of Science ®Google Scholar
• Nakatani Y, Matsumura M, Monden T, et al. Improvement of glycemic control by re-education in insulin injection technique in patients with diabetes mellitus. Adv Ther. 2013;30(10):897–906.
   PubMed Web of Science ®Google Scholar
• Fujioka K, Sparre T, Sun LYH, et al. Usability of the novel Liraglutide 3.0 mg pen injector among overweight or obese adult patients with or without prior injection experience. J Diabetes Sci Technol. 2016;10(1):164–174.
   Google Scholar
• Guerlain S, Hugine A, Wang L. A comparison of 4 epinephrine autoinjector delivery systems: usability and patient preference. Ann Allergy Asthma Immunol. 2010;104(2):172–177.
   PubMed Web of Science ®Google Scholar
• Shemesh E, Knight C, Rubes M, et al. Food-allergic adolescents at risk for anaphylaxis: a randomized controlled study of supervised injection to improve comfort with epinephrine self-injection. J Allergy Clin Immunol Pract. 2017;5(2):391–397.
   PubMed Web of Science ®Google Scholar
• Kettel L, Scholl G, Bonaventura L, et al. Evaluation of a pen device for self-administration of recombinant human FSH in clomiphene citrate-resistant anovulatory women undergoing ovulation induction. Reprod Biomed Online. 2004;9(4):373–380.
   PubMed Web of Science ®Google Scholar
• Kaplan I, Ross D, Hilton F, et al. The role of training in effective simulated self-injection of subcutaneous depot medroxyprogesterone acetate: observations from a usability study. Contraception. 2016;94(4):314–320.
   PubMed Web of Science ®Google Scholar
• Schiff M, Koo J, Jin E, et al. Usability and acceptability of the abatacept pre-filled autoinjector for the subcutaneous treatment of rheumatoid arthritis. Adv Ther. 2016;33(2):199–213.
   PubMed Web of Science ®Google Scholar
• Schwartz S. Correct use of a new reusable insulin injection pen by patients with diabetes: a design validation study. J Diabetes Sci Technol. 2010;4(5):1229–1235.
   PubMedGoogle Scholar
• Lange J, Richard P, Bradley N. Usability of devices for self-injection: results of a formative study on a new disposable pen injector. Med Devices (Auckl). 2014;7(1):195–203.
   PubMedGoogle Scholar
• Duffin KC, Bukhalo M, Bobonich MA, et al. Usability of a novel disposable autoinjector device for ixekizumab: Results from a qualitative study and an open-label clinical trial, including patient-reported experience. Med Devices. 2016;9:361–369.
   Google Scholar
• Richards H, Fortune D, Griffiths C. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venerol . 2006;20(4):370–379.
   PubMed Web of Science ®Google Scholar
• Renzi C, Abeni D, Picardi A, et al. Factors associated with patient satisfaction with care among dermatological outpatients. Br J Dermatol. 2001;145(4):617–623.
   PubMed Web of Science ®Google Scholar
• Vangeli E, Bakhshi S, Baker A, et al. A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther. 2015;32(11):983–1028.
   PubMed Web of Science ®Google Scholar
• Leung YY, Tam LS, Lee KW, et al. Involvement, satisfaction and unmet health care needs in patients with psoriatic arthritis. Rheumatology (Oxford). 2008;48(1):53–56.
   PubMed Web of Science ®Google Scholar
• Hudry C, Lebrun A, Moura B, et al. Evaluation of usability and acceptance of a new autoinjector intended for methotrexate subcutaneous self-administration in the management of rheumatoid arthritis. Rheumatol Ther. 2017;4(1):183–194.
   PubMed Web of Science ®Google Scholar
• LaRue S, Malloy J. Evaluation of the dual-chamber pen design for the injection of exenatide once weekly for the treatment of type 2 diabetes. J Diabetes Sci Technol. 2015;9(4):815–821.
   PubMedGoogle Scholar
• Freundlich B, Kivitz A, Jaffe JS. Nearly pain-free self-administration of subcutaneous methotrexate with an autoinjector: results of a phase 2 clinical trial in patients with rheumatoid arthritis who have functional limitations. J Clin Rheumatol. 2014;20(5):256–260.
   PubMed Web of Science ®Google Scholar
• Utsunomiya T, Tanaka A, Tatsumi K, et al. A questionnaire-based survey to assess patient satisfaction, ease-of-learning, ease-of-use, injection site pain and overall patient satisfaction of the follitropin-alpha (Gonal-f) filled-by-mass (FbM) prefilled pen compared with other systems of gonadotrophin administration. Reprod Biol Endocrinol. 2012;10:93.
   PubMed Web of Science ®Google Scholar
• Katz SJ, Leung S. Teaching methotrexate self-injection with a web-based video maintains patient care while reducing healthcare resources: a pilot study. Rheumatol Int. 2015;35(1):93–96.
   PubMed Web of Science ®Google Scholar
• Rittberg R, Dissanayake T, Katz SJ. A qualitative analysis of methotrexate self-injection education videos on YouTube. Clin Rheumatol. 2016;35(5):1329–1333.
   PubMed Web of Science ®Google Scholar
• Singh AG, Singh S, Singh PP. YouTube for information on rheumatoid arthritis: a wakeup call? J Rheumatol. 2012;39(5):899–903.
   PubMed Web of Science ®Google Scholar
• Demary W, Schwenke H, Rockwitz K, et al. Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: Patient preference and comparison of the self-injection experience. Patient Prefer Adherence. 2014;8:1061–1071.
   PubMed Web of Science ®Google Scholar
• Berteau C, Schwarzenbach F, Donazzolo Y, et al. Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers. Patient Prefer Adherence. 2010;4:379–388.
   PubMed Web of Science ®Google Scholar
• Ignaut DA, Schwartz SL, Sarwat S, et al. Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen. Diabetes Educ. 2009;35(5):789–798.
   PubMed Web of Science ®Google Scholar
• Lim WH, Chan D, Boudville N, et al. Patients’ perceptions of subcutaneous delivery of darbepoetin alfa by autoinjector prefilled pen versus prefilled syringe: a randomized, crossover study. Clin Ther. 2012;34(9):1948–1953.
   PubMed Web of Science ®Google Scholar
• Korytkowski M, Bell D, Jacobsen C, et al. A. Multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836–2848.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Ortonne JP. Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy. J Cutan Med Surg. 2004;8(5):310–320.
   PubMed Web of Science ®Google Scholar
• Callis Duffin K, Bagel J, Bukhalo M, et al. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). J Eur Acad Dermatol Venereol. 2017;31(1):107–113.
   PubMed Web of Science ®Google Scholar
• Struemper H, Murtaugh T, Gilbert J, et al. Relative bioavailability of a single dose of belimumab administered subcutaneously by prefilled syringe or autoinjector in healthy subjects. Clin Pharmacol Drug Dev. 2016;5(3):208–215.
   PubMed Web of Science ®Google Scholar
• Pozzilli C, Schweikert B, Ecari U, et al. Supportive strategies to improve adherence to IFN beta-1b in multiple sclerosis-results of the BetaPlus observational cohort study. J Neurol Sci. 2011;307(1–2):120–126.
   PubMed Web of Science ®Google Scholar
• Govender D, Ross A. Sharps disposal practices among diabetic patients using insulin. S Afr Med J. 2012;102(3):163–164.
   PubMed Web of Science ®Google Scholar
• Cunha GH, Barbosa RVA, Fontenele MSM, et al. Insulin therapy waste produced in the households of people with diabetes monitored in primary care. Rev Bras Enferm. 2017;70(3):618–625.
   PubMed Web of Science ®Google Scholar
• Ishtiaq O, Qadri AM, Mehar S, et al. Disposal of syringes, needles, and lancets used by diabetic patients in Pakistan. J Infect Public Health. 2012;5(2):182–188.
   PubMedGoogle Scholar
• Olowokure B, Duggal H, Armitage L. The disposal of used sharps by diabetic patients living at home. Int J Environ Health Res. 2003;13(2):117–123.
   PubMed Web of Science ®Google Scholar
• Basazn Mekuria A, Melaku Gebresillassie B, Asfaw Erku D, et al. Knowledge and self-reported practice of insulin injection device disposal among diabetes patients in Gondar Town, Ethiopia: a cross-sectional study. J Diabetes Res. 2016;2016:1–7.
   Web of Science ®Google Scholar